Genetic screening for haematological cancers

Screening for haematological cancers is costly and time-consuming. The standard screening procedure, which looks for mutations in four specific genes, costs about $300 and can take seven to 10 days to return complete results. To allay the costs involved, many hospitals wait for a batch of samples from multiple patients before running the test. Precipio, based in New Haven, has now advanced the state of care with the commercial launch of HemeScreen, a novel proprietary test for mutations in haematological cancers.

Importantly, the HemeScreen assay can deliver results in four to six hours rather than days, enabling a same-day turnaround time. Equally important, the HemeScreen assay also costs a fraction of the current technologies to run. At $100, this is about one-third of the cost of the traditional method, making the potential savings substantial.

 

Other news

Upcoming Events

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Feb 2019

Early disease detection: a collaborative approach

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.